NCT07205224

Inflammatory Response Under Spinal vs General Anesthesia in PCNL: NLR, RDW, LAR.

Effects of Spinal Versus General Anesthesia on Perioperative Inflammatory Response in Percutaneous Nephrolithotomy (PCNL): The Role of Neutrophil-to-Lymphocyte Ratio (NLR), Red Cell Distribution Width (RDW), and Lactate-to-Albumin Ratio (LAR)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 90 (actual)
• Sponsor: Sevim Şenol Karataş · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This observational study compares the effects of spinal versus general anesthesia on the perioperative systemic inflammatory response in adults undergoing PCNL. Routine clinical laboratory values (NLR, RDW, LAR) obtained preoperatively and postoperatively will be recorded to evaluate between-group and within-group changes. No additional blood sampling will be performed beyond standard care.

Detailed description

The study will be conducted at the Department of Anesthesiology and Reanimation, Elazığ Fethi Sekin City Hospital, among adult patients scheduled for PCNL (ASA I-III). The anesthesia type (spinal vs general) is determined by clinical requirements; investigators do not influence this choice. Sampling windows: Preoperative: within ≤6 hours before surgery Postoperative: first sample obtained within 6-24 hours after surgery Parameters: NLR (neutrophil/lymphocyte), RDW, LAR; plus age, sex, ASA class, operative time, and in-hospital complications. Statistics: Normality testing; between-group comparisons by independent t-test or Mann-Whitney U; within-group by paired t-test or Wilcoxon; categorical by chi-square; p\<0.05 significant. Power considerations target ≥45 per group (total ≥90). No extra biospecimens will be collected beyond routine care.

Conditions

• Nephrolithiasis
• Postoperative Inflammation

Interventions

Type	Name	Description
OTHER	Anesthesia Type	Patients receive either spinal or general anesthesia according to routine clinical decision-making. No investigational drug or device is administered.

Timeline

• Start date: 2025-09-22
• Primary completion: 2025-10-22
• Completion: 2025-10-22
• First posted: 2025-10-03
• Last updated: 2025-11-26

Locations

1 site across 1 country: Turkey (Türkiye)